Type

Journal Article

Authors

K O'Byrne
M Seckl
S Cuffe
F Mauri
B Al-Alao
K Gately

Subjects

Medicine & Nursing

Topics
neoplasm invasiveness tor serine threonine kinases physiology humans middle aged mortality adult aged female chemistry prognosis carcinoma non small cell lung aged 80 and over blood vessels mtor protein human pathology neoplasm staging male lung neoplasms

Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. (2011)

Abstract A recent study by Dhillon et al. [12], identified both angioinvasion and mTOR as prognostic biomarkers for poor survival in early stage NSCLC. The aim of this study was to verify the above study by examining the angioinvasion and mTOR expression profile in a cohort of early stage NSCLC patients and correlate the results to patient clinico-pathological data and survival. Angioinvasion was routinely recorded by the pathologist at the initial assessment of the tumor following resection. mTOR was evaluated in 141 early stage (IA-IIB) NSCLC patients (67 - squamous; 60 - adenocarcinoma; 14 - others) using immunohistochemistry (IHC) analysis with an immunohistochemical score (IHS) calculated (% positive cells×staining intensity). Intensity was scored as follows: 0 (negative); 1+ (weak); 2+ (moderate); 3+ (strong). The range of scores was 0-300. Based on the previous study a cut-off score of 30 was used to define positive versus negative patients. The impact of angioinvasion and mTOR expression on prognosis was then evaluated. 101 of the 141 tumors studied expressed mTOR. There was no difference in mTOR expression between squamous cell carcinoma and adenocarcinoma. Angioinvasion (p=0.024) and mTOR staining (p=0.048) were significant univariate predictors of poor survival. Both remained significant after multivariate analysis (p=0.037 and p=0.020, respectively). Our findings verify angioinvasion and mTOR expression as new biomarkers for poor outcome in patients with early stage NSCLC. mTOR expressing patients may benefit from novel therapies targeting the mTOR survival pathway.
Collections Ireland -> Trinity College Dublin -> PubMed

Full list of authors on original publication

K O'Byrne, M Seckl, S Cuffe, F Mauri, B Al-Alao, K Gately

Experts in our system

1
Ken O'Byrne
Trinity College Dublin
Total Publications: 49
 
2
Sinead Cuffe
Trinity College Dublin
Total Publications: 21
 
3
Kathy Gately
Trinity College Dublin
Total Publications: 22